Today, (7th June), Cyprotex announces that it has enhanced the Cloe® Screen product offering to include an in vitro assay that assesses the extent to which a compound binds to liver microsomes. When used in conjunction with microsomal stability data, correction for microsomal binding can improve the prediction of a compound’s in vivo clearance and potential for drug-drug interactions. The Cyprotex Cloe® Screen microsomal binding assay was designed in response to requests from biotechnology and pharmaceutical companies who work with Cyprotex’ to evaluate potential drug candidates.
Mr. Robert Morrison Atwater, Cyprotex’ Chief Executive Officer, comments on the launch of the new service ‘Once again Cyprotex proves itself to be foremost in the provision of in vitro ADMET services. By offering this service we are adding to our extensive portfolio of services and reinforcing Cyprotex’ position as a leader within the industry. Similarly to existing Cloe® Screen assays, the microsomal binding assay is invaluable in enabling companies to make informed decisions when selecting compounds to progress further within the drug discovery process.’
Cyprotex is a specialist provider of ADME data and pharmacokinetic predictive services. The unique Cloe® Screen technology which couples robust protocols with state-of-the-art automation enables Cyprotex to offer an unrivalled combination of high quality, cost effective data with rapid turnaround. By using data from the Cloe® Screen microsomal binding assay in conjunction with the existing Cloe® Screen microsomal stability, a more accurate prediction of the rate at which a drug is metabolised in vivo is determined than by means of microsomal stability data alone. The data can also be applied to improving in vivo drug-drug interaction predictions.
For further information:
Francesca Sadler, Marketing Manager
Tel: +44 1625 505 100